Gene symbol | ABCD1 | Synonyms | ABC42, ALD, ALDP, AMN | Type of gene | protein-coding |
Chromosome | X | Map location | Xq28 | dbXrefs | |
Description | ATP binding cassette subfamily D member 1 |
GTO ID | GTC3047 |
Trial ID | NCT05394064 |
Disease | Adrenomyeloneuropathy |
Altered gene | ABCD1 |
Therapeutic/Target gene | Therapeutic gene |
Therapy | Gene transfer |
Treatment | SBT101 |
Phase | Phase1|Phase2 |
Recruitment status | Recruiting |
Title | A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients With Adrenomyeloneuropathy |
Year | 2022 |
Country | Netherlands|United States |
Company sponsor | SwanBio Therapeutics, Inc. |
Other ID(s) | SBT101-CT101|2021-004410-19 |
Vector information | |||||||||
|
Cohort 1 | |||||||
|